The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China

OBJECTIVE: The aim of this study was to investigate the cost-effectiveness of serplulimab versus regorafenib in previously treated unresectable or metastatic microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) colorectal cancer in China. METHODS: From the perspective of China’s...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yue, Zhou, Jiting, Ye, Yuxin, Wang, Xintian, Ma, Aixia, Li, Hongchao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171919/
https://www.ncbi.nlm.nih.gov/pubmed/37182176
http://dx.doi.org/10.3389/fonc.2023.1113346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171919/
https://www.ncbi.nlm.nih.gov/pubmed/37182176
http://dx.doi.org/10.3389/fonc.2023.1113346

Ejemplares similares